Aurinia Pharmaceuticals (AUPH) Proxy Filing summary

Executive summary

• Annual General Meeting scheduled for June 14, 2024, with key proposals to be voted on, including amendments to the Equity Incentive Plan.

• Supplement reduces the proposed increase in shares reserved for the Equity Incentive Plan from 11,375,000 to 8,500,000, now totaling 32,315,115 shares or 22.7% of outstanding shares as of April 30, 2024.

• The Plan Amendment was further approved by the Board on June 3, 2024.

Voting matters and shareholder proposals

• Shareholders will vote on the amendment and restatement of the Equity Incentive Plan to increase the maximum fixed number of common shares reserved for issuance from 23,815,115 to 32,315,115.

• Voting can be conducted online, by mail, telephone, or internet, with detailed procedures provided.

• Shareholders who have already submitted proxies may revoke or change their votes before the meeting.

Board of directors and corporate governance

• The Board retains authority to administer, interpret, and amend the Equity Incentive Plan, including delegating powers to committees.

• The Board is responsible for determining eligibility, terms, and conditions of awards under the plan.